Vigorous Gainers/Losers Roundup: AGNC Investment (NASDAQ:AGNC), Amgen (NASDAQ:AMGN)

AGNC Investment Corp. (NASDAQ:AGNC) [Trend Analysis] luring active investment momentum, shares an advance 0.76% to $19.27. AGNC Investment Corp. (AGNC) reported that its Board of Directors has declared a cash dividend of $0.18 per share of common stock for March 2017. The dividend is payable on April 7, 2017 to common stockholders of record as of March 31, 2017, with an ex-dividend date of March 29, 2017.

The Company also reported its estimated net book value of $21.17 per common share and estimated net tangible book value of $19.50 per common share as of February 28, 2017. The estimates of net book value and net tangible book value include deductions for the Company’s February 2017 dividend of $0.18 per common share, which was declared on February 14, 2017 with a February 28, 2017 record date. The Company’s estimated net tangible book value of $19.50 per common share excludes intangible assets recognized by the Company in connection with the acquisition of AGNC Mortgage Management, LLC and the internalization of the Company’s management on July 1, 2016. The total volume of 512726 shares held in the session was surprisingly higher than its average volume of 3150.82 shares. EPS estimates indicating constrictive facts, the current year from sell-side analysts, Price to current year EPS stands at 234.20%, and looking further price to next year’s EPS is -2.10%. While take a short look on price to sales ratio, that was 5.65 and price to earnings ratio of 10.51 attracting passive investors.

Several matter pinch shares of Amgen Inc. (NASDAQ:AMGN) [Trend Analysis], as shares surging 1.15% to $182.20 with a share volume of 903079. Amgen (AMGN) reported that a Phase 3 study evaluating Repatha in patients who were receiving apheresis to reduce low-density lipoprotein cholesterol met its primary endpoint, demonstrating that treatment with Repatha importantly reduced the need for LDL-C apheresis in adult patients, as measured at the end of the randomized period.

The study also met its secondary endpoints of percent change from baseline to week 4 in LDL-C, non-high-density lipoprotein cholesterol and total cholesterol:HDL-C ratio. The overall incidence of treatment-emergent adverse events was comparable among both groups. No new safety concerns were identified in the study.Apheresis is an invasive procedure similar to dialysis, in which a special machine removes LDL-C from a patient’s plasma. The stock is going forward its 52-week low with 38.20% and moving down from its 52-week high price with 0.11%. To have technical analysis views, liquidity ratio of a company was calculated 4.10 as evaluated with its debt to equity ratio of 1.16. The float short ratio was 1.19%, as compared to sentiment indicator; Short Ratio was 2.57.


About Aaron Smithies

Aaron Smithies has a wide look on current monetary and financial events. He is an editor and a writer. His views; At Streetwise Report, we think the best opportunities arise from a complete understanding of all investing disciplines in order to identify the most attractive stocks at any given time. Interests: Biotech, Finical markets, Dividend stock ideas & income, Energy stocks, Consumer goods stocks

Leave a Reply

Your email address will not be published. Required fields are marked *